Daiichi Sankyo: New data further strengthens important role

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1

Related Keywords

Wolfgang Schiessl , Stefan Seyfried , Daiichi Sankyo , Daiichi Sankyo Europe , Daiichi Sankyo Europe Gmb , University Of Pisa , European Society Of Cardiology Congress , Pisa University Hospital , Sustainable Development Of Society , Innovative Global Healthcare Company , European Society Of Cardiology , European Heart Rhythm Association Practical , University Cardiology Division , Edoxaban Clinical Research Programme , Europe Registry , European Society , Sankyo Europe , Cardiology Congress , Raffaele De Caterina , Pisa University , Vice President , Medical Affairs , Specialty Medicines , Global Healthcare Company Contributing , Sustainable Development , Exodaban Treatment , Atrial Fibrillation , Heart Rhythm Association Practical Guide , Non Vitamink Antagonist Oral Anticoagulants , Sankyo Europe Gmbh , Communication Lead , Daiichi , Sankyo , Data , Urther , Trengthens , Important , Sole , Dixiana , Edoxaban , Managing , Complex , Patient , Populations , Trial , Defibrillation ,